Guardant Health, Inc. (GH): Price and Financial Metrics

Guardant Health, Inc. (GH): $29.64

0.42 (-1.40%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

GH Price/Volume Stats

Current price $29.64 52-week high $62.75
Prev. close $30.06 52-week low $20.67
Day low $28.47 Volume 2,584,500
Day high $30.66 Avg. volume 1,922,636
50-day MA $34.56 Dividend yield N/A
200-day MA $30.90 Market Cap 3.49B

GH Stock Price Chart Interactive Chart >

GH POWR Grades

  • GH scores best on the Growth dimension, with a Growth rank ahead of 76.35% of US stocks.
  • GH's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • GH ranks lowest in Momentum; there it ranks in the 5th percentile.

GH Stock Summary

  • GH's went public 4.98 years ago, making it older than only 21.17% of listed US stocks we're tracking.
  • With a price/sales ratio of 5.98, GUARDANT HEALTH INC has a higher such ratio than 83.82% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 14.03 for GUARDANT HEALTH INC; that's greater than it is for 94.98% of US stocks.
  • If you're looking for stocks that are quantitatively similar to GUARDANT HEALTH INC, a group of peers worth examining would be ASXC, FCEL, WATT, TVTX, and AXDX.
  • GH's SEC filings can be seen here. And to visit GUARDANT HEALTH INC's official web site, go to guardanthealth.com.

GH Valuation Summary

  • In comparison to the median Healthcare stock, GH's price/sales ratio is 215.79% higher, now standing at 6.
  • Over the past 60 months, GH's price/sales ratio has gone down 48.

Below are key valuation metrics over time for GH.

Stock Date P/S P/B P/E EV/EBIT
GH 2023-09-22 6.0 10.4 -6.0 -8.2
GH 2023-09-21 6.0 10.5 -6.0 -8.2
GH 2023-09-20 6.3 11.0 -6.3 -8.5
GH 2023-09-19 6.4 11.1 -6.4 -8.6
GH 2023-09-18 6.6 11.4 -6.6 -8.8
GH 2023-09-15 6.8 11.9 -6.8 -9.0

GH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GH has a Quality Grade of C, ranking ahead of 48.47% of graded US stocks.
  • GH's asset turnover comes in at 0.158 -- ranking 71st of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows GH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.158 0.665 -0.174
2021-03-31 0.166 0.662 -0.187
2020-12-31 0.199 0.677 -0.197
2020-09-30 0.244 0.683 -0.205
2020-06-30 0.249 0.677 -0.147
2020-03-31 0.258 0.683 -0.108

GH Price Target

For more insight on analysts targets of GH, see our GH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $167.39 Average Broker Recommendation 1.27 (Strong Buy)

Guardant Health, Inc. (GH) Company Bio


Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was founded in 2011 and is based in Redwood City, California.


GH Latest News Stream


Event/Time News Detail
Loading, please wait...

GH Latest Social Stream


Loading social stream, please wait...

View Full GH Social Stream

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?

Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | September 29, 2023

Why Guardant Health Stock Jumped 15% This Week

The precision oncology leader benefited from a pair of positive analyst notes this week. Here's what investors need to know.

Yahoo | September 28, 2023

Why Guardant Health Stock Popped Again Today

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (NASDAQ: GH) haven't had a lot to cheer about this year. Combined with an even stronger rise from an unrelated analyst upgrade yesterday, this means Guardant shares have now risen more than 12% total over two days of trading. As The Fly reports, Bernstein initiated coverage of Guardant with an outperform (i.e., buy) rating and a $34 price target, citing the company's high and growing levels of recurring revenue (helped by a "locked-in" customer base), high profit margin on that revenue, and strong growth prospects.

Yahoo | September 28, 2023

Guardant Health Inc (GH): A Deep Dive into Its Performance Potential

Unraveling the Factors That Could Limit Guardant Health Inc's Outperformance

Yahoo | September 27, 2023

Guardant Health (GH): A Potential Value Trap?

An In-Depth Analysis of the Risks and Rewards

Yahoo | September 27, 2023

Read More 'GH' Stories Here

GH Price Returns

1-mo -15.34%
3-mo N/A
6-mo 25.59%
1-year -44.94%
3-year -72.61%
5-year N/A
YTD 8.97%
2022 -72.81%
2021 -22.39%
2020 64.93%
2019 107.87%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!